Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		1440000			(OB RECEIPTO	3 1 JAN 2005
Substitu	ite ioi i	form 1449/PTO			Application Number	TBA TOTAL	O I ONIT KUU
	TRI	EODALATEL	AN DIC	CI OCIDE	Filing Date	January 31, 2005	
INFORMATION DISCLOSURE					First Named Inventor	Ferenc Buzsaky	
i '	SI	CATEMENT	BY AP	PLICANT	Art Unit	TBA-1615	
	~ -	(Use as many			Examiner Name	TBA-HASAN S, 1	HIMED
Sheet		1	of	2	Attorney Docket Number	1103326-0786	

		U.S	. PATENT DOCU	MENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee	Pages, Columns, Lines, Where
Initials	No.1	Number-Kind Code ² ((brown)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages/Figures Appear
10		US-4,784,858	11-15-1988	Ventouras	
7		US-5,292,522	03-08-1994	Petereit et al.	
7		US-5,478,573	12-26-1995	Eichel et al.	
(Va)		US-5,871,776	02-16-1999	Mehta	

		FOREIGN	PATENT DOC	UMENTS		
Examiner Initials	Cite No.	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	To
40		WO 02/058677-A1	08-01-2002	Hölzer et al.		
Ja		WO 03/051340-A1	06-26-2003	Hjartstam et al.		
		NON PATENT	LITERATURE	DOCUMENTS		<u> </u>
Examiner nitials	Cite No.	Include name of the author (in CAPITAL LETT serial, symposium, catalog, etc.), date, pa	TERS), title of the articl age(s), volume-issue nu	e (when appropriate), title of t imber(s), publisher, city and/o	he item (book, magazine, journal, r country where published.	Т
4a		LIN et al., AAPS Pharmasci., volume 3	(2), article 14, 200	1, pages 1-12.		
1		WESSELING et al., European Journal of pages 73-78.	of Pharmaceutics an	d Biopharmaceutics, volu	ите 47, по. 1, 1999,	
		MATHIR et al., J. Microencapsulation,	volume 14, no. 6, 1	997, pages 743-751.		
		PETEREIT et al., European Journal of F pages 15-25.	Pharmaceutics and I	Biopharmaceuties, volum	e 47, no. 1, 1999,	
		PETEREIT et al., European Journal of I pages 219-228.	Pharmaceutics and l	Biopharmaceutics, vol. 41	, no. 4, August 1, 1995,	
		RAGNARSSON et al., Drug Develop. a	and Ind. Pharmacy,	vol. 13, pages 1495-1509	(1987).	To
		SANDBERG et al., European Journal o	f Clin. Pharmacol.,	vol. 33 (1988), pages S3-	S7 and S9-S14.	
		RAGNARSSON et al., International Jou	urnal of Pharmaceu	tics, vol. 79, pages 223-2	32 (1992).	
V		SANDBERG et al., International Journa	al of Pharmaceutics	, vol. 68, pages 167-177 ((1991).	
Ha		SANDBERG et al., Pharmaceutical Res	earch, vol. 10, page	es 28-34 (1993).		
·	-		<u> </u>			
		LALA A	· · · · · ·	In a succession	6 T 62-4	_
Examiner Si	gnature			Date Considered	I A CHANNEY SOOP	<u> </u>

"EXAMINER: Initial if reference considered, whether or not citation is an conformance with MPEP 609. Draw line through citation if not in conformance and not considered, because copy of this form with next communication to applicant. "Applicant is unique citation designation member (optional). See Klods Codes of USFTO Patent Documents in https://www.espto.gov/ or MPEP 901.04. "Exter Office that issued the document, by the two-letter code (WIPO Standard ST.1.9). "For Jupanese patent documents, the indication of the year of the reign of the Emporer must precede the serial number of the patent document. Wind of documents by the appropriate rymbols as indicated on the document mader WIPO Standard ST.1.6 if possible. "Applicant is to place the che must be referred by 15 US.C. 122 and 37 CFR 1.14. This collection of information is required by 51 TOF PA. 1978 the information is received to be sent by the public which is to file (and by the USFTO to process) as application. Confidentially is governed by 35 US.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, prograing, and enhantising the completed application form to the USFTO. Time will vary depending upon the individual tases. Any comments on the emmonst of time you require to complete this formation for reducing this beaution. Confidentially comments on the emmonst of time you require to complete this formation of fire formation of file formation of officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/523553

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

0.1 viv. 6 . 6 . 1440PTO				***************************************	Esh.	HPIEHOG/E	KRETIPTO	31	JAN 2005	
Substitut	obstitute for form 1449/PTO				Application Number	ТВА	:•			
	TATECODAYATE	ORT T) TC	OI OCIDE	Filing Date	January	31, 2005			
INFORMATION DISCLOSURE					First Named Inventor	Ferenc Buzsaky				
	STATEMENT	BY	AI	PPLICANT	Art Unit	TBA	L15			
	(Use as many				Examiner Name	TOR	YOUNG AN	med	,	
Sheet	2		of	2	Attorney Docket Number	110332				

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1
110		SANDBERG et al., Drug Invest., vol. 6, pages 320-329 (1993).	
1		AMIGHI AND MOËS, S.T.P. Pharma Sci., vol. 7(2), pages 141-147 (1997).	
		BODMEIER AND PAERATAKUL, Pharm. Res., vol. 11(6), pages 882-888 (1994).	
		OZTURK et al., J. Controlled Release, vol. 14, pages 203-213 (1990).	
		GOODHART et al., Pharmaceutical Tech., April 1984, pages 64-71.	
		BODMEIER AND PAERATAKUL, International Journal of Pharmaceutics, vol. 152, pages 17-26 (1997).	
V		BODMEIER AND PAERATAKUL, Drug Develop. and Ind. Pharmacy, vol. 20(9), pages 1517-1533 (1994).	
310		SPERLING et al., Journal of Applied Polymer Science, vol. 14, page 73-78 (1970).	
· · · · · ·			-
		·	
	1	1.1.0	
Examiner Sig	nature	Date Considered & Santable 2015	\neg

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next commandation to applicant, 'Applicant's unique citation designation number (optionals). See Kinds Codes of USFTO Patent Documents at wave application. Code of USFTO Patent Documents at wave application of the year of the rigin of the Emparty many precede the serial number of the patent of the option of the year of the rigin of the Emparty many precede the serial number of the patent of the special of the option of the year of the rigin of the Emparty many preceded to the document by the proporties special on the document of the patent and contents. What of document by the perpential proposal and the special proposal is applicated in the proposal proposal proposal and a should find the standard ST-13. For information is required to obtain or retain a benefit by the public which is to file (and by the USFTO in process) as explicated. Conformatistic is governed by 33 USC. 127 and 17 CFR 1-14. This collection is established to the completed application form to the USFTO. Time will very depending upon the individual case. Any comments on the amount of time year require to complete this form moder atgressions for retaining this bardon, should be sent to the Chief Information Officer, U.S. Patent and Tradomart Office, P.O. Box 1450, Alexandria, VA 22313-1450.

**DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.